Invesco WilderHill Clean Energy ETF vs Sana Biotechnology Inc — how do they compare? Invesco WilderHill Clean Energy ETF trades at $33.85, while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: Invesco WilderHill Clean Energy ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| PBW | SANA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $46.99 | $5.92 |
52-Week Low | $22.23 | $2.68 |
Market Cap | — | $879.40M |
Enterprise Value | — | $853.59M |
Signals from Pluang's Aura AI — not financial advice
PBW trades at $33.21, down 0.54% today, amid a bearish technical signal with moving averages indicating strong selling pressure. The ETF shows oversold conditions on short-term RSI readings but faces headwinds from sector volatility. Recent news highlights clean energy's potential tailwinds from energy security concerns and data center demand, though the fund remains sensitive to interest rate movements and semiconductor market swings.
The outlook for PBW is cautious; while clean energy thematic demand provides long-term opportunity, near-term risks include interest rate sensitivity and tech sector correlation. Investors face volatility from macroeconomic factors and sector-specific pressures, requiring careful risk assessment amid mixed technical and fundamental signals.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Trailing returns across standard periods
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →